ClinicalTrials.gg
RecruitingNCT06086704Updated Aug 31, 2026

Study of 18F-FFNP Breast PET/MRI

A Phase 2 interventional study of 18F-fluorofuranylnorprogesterone and Positron Emissions Tomography / Magnetic Resonance Imaging in Breast Cancer, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by University of Wisconsin, Madison · Phase 2, Interventional, and Diagnostic

How we know · 4 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Breast Neoplasms by University of Wisconsin, Madison — 6 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · University of Wisconsin, Madison.

Planned enrollment
14th of 43
53 · median 29
Started
2024
with 2 others
Phase 2
18 of 52
4 open now
Registered
50th of 52
by date

Among the 52 studies in Breast Neoplasms by University of Wisconsin, Madison, this one is the 14th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 in phase 2, and was the 50th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 52 studies in Breast Neoplasms by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Breast Neoplasms by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.

Read the detailed description

Primary Objective

  • Determine the diagnostic accuracy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy.

Secondary Objectives

  • Determine the repeatability of quantitative assessment of tumor 18F-FFNP uptake.
  • Determine the intra- and inter-observer variability of quantitative assessment of tumor 18F-FFNP uptake.
  • Assess the safety and tolerability of 18F-FFNP.

Exploratory Objectives

  • Define the parent and metabolite fractions of 18F-FFNP over the time course of the scan.
  • Assess the association between tumor 18F-FFNP uptake with serum progesterone, estradiol, and corticosteroid binding globulin levels.
  • Compare changes in 18F-FFNP breast PET/MRI parameters with changes in PR immunohistochemistry in therapy responders and non-responders.
  • Assess the association between tumor 18F-FFNP uptake with disease recurrence.
  • Determine whether MRI parameters improve the predictive value of FFNP PET alone.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • PR+
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • status defined by either

    • prior bilateral oophorectomy
    • age greater than or equal to 60 years of age
    • age less than 60 years of age and amenorrheic for 12 or more months in the absence of prior chemotherapy, tamoxifen, toremifene or ovarian suppression and FSH and estradiol in the postmenopausal range per local normal range (Group 2 only)
  • Diagnosis of -proven invasive breast cancer measuring at least 1.0 cm in diameter by any imaging modality. may be located within the breast, axilla (e.g. axillary lymph node), or both the breast and axilla
  • Biopsy-proven PR-positive invasive breast cancer
  • Definitive surgical excision of the primary tumor planned without therapy; defined as therapy (chemotherapy, targeted therapy, radiation therapy or endocrine therapy) given to decrease the size of the tumor prior to planned surgery. (Group 2 only)

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide to the study
  • -positive breast cancer, as defined by immunohistochemical staining 3+ OR positive by in situ hybridization (Group 2 only)
  • PR and Ki67 IHC slides or FFPE tissue blocks from clinical breast not available
  • Patients who have completed chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven (Group 2 only)
  • Patients who are planning to undergo anastrozole as standard of care neoadjuvant therapy
  • Patients who are currently taking aromatase inhibitors or ER antagonists (tamoxifen, raloxifene)
  • Patients with breast expanders
  • Patients who are pregnant or lactating
  • Patients with clinical for use of aromatase inhibitors (AI) while on study as determined by investigator (Group 2 only)
  • Patients with a contraindication to gadolinium-based contrast agents, including allergy or impaired renal function (per UW Health Guidelines)
  • Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FFNP
  • Patients with history of allergic reaction to anastrozole (Group 2 only)
  • Patients in liver failure as judged by the patient's physician
  • Patients with standard contraindications to MRI (per UW Health Guidelines)
  • Patients requiring conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:

    • The patient has their own prescription for the medication
    • The informed consent process is conducted prior to the self-administration of the medication.
    • The patient comes to the research visit with a driver.
  • Patients unable to lie prone for 45 minutes for imaging
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    Group 1: Metabolite Analysis

    participants will undergo venous blood sampling during the PET/MRI scan

    Drug: 18F-fluorofuranylnorprogesterone · Device: Positron Emissions Tomography / Magnetic Resonance Imaging · Other: Blood Sampling · Drug: FDA-approved gadolinium-based intravenous contrast agent

  • Experimental
    Group 2: Pre-surgical Treatment

    participants will undergo PET/MRI scans before and after 2 weeks treatment with anastrozole

    Drug: 18F-fluorofuranylnorprogesterone · Device: Positron Emissions Tomography / Magnetic Resonance Imaging · Drug: Anastrozole · Drug: FDA-approved gadolinium-based intravenous contrast agent

  • Experimental
    Group 3: Test-Retest

    participants will undergo baseline and repeat PET/MRI scans without intervening treatment to determine repeatability

    Drug: 18F-fluorofuranylnorprogesterone · Device: Positron Emissions Tomography / Magnetic Resonance Imaging · Drug: FDA-approved gadolinium-based intravenous contrast agent

Interventions

  • Drug18F-fluorofuranylnorprogesterone

    18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.

    Also known as: FFNP

  • DevicePositron Emissions Tomography / Magnetic Resonance Imaging

    Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)

    Also known as: PET/MRI

  • hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days

  • OtherBlood Sampling

    Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions

  • DrugFDA-approved gadolinium-based intravenous contrast agent

    FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study

    Also known as: gadopiclenol, gadobenate dimuglumine

06

What researchers measure

Primary outcomes

  1. Percentage change in 18F-FFNP uptake between baseline and follow-up PET/MRI scans

    Tumor uptake values of 18F-FFNP will be obtained from the attenuation corrected PET component of the simultaneous breast 18F-FFNP PET/MRI research scan according to the procedures detailed in the imaging manual and the FDA IND.

    Time frame: up to 4 weeks on study and up to 7 weeks on study

  2. Percentage change in tumor Ki67 proliferation score, as a surrogate measure of endocrine sensitivity

    Baseline Ki67 proliferation immunohistochemistry score will be obtained from the existing clinical standard-of-care breast biopsy. Post-treatment K67 proliferation immunohistochemistry score will be obtained from the surgical specimen after excision. Treatment response is defined as a reduction in Ki67 score of greater than or equal to 60 percent. Treatment nonresponse is defined as a reduction of less than 60 percent.

    Time frame: up to 4 weeks on study and up to 7 weeks on study

Secondary outcomes

  1. Qualitative Analysis of 18F-FFNP uptake

    18F-FFNP uptake will be visually evaluated qualitatively with the following grading scale: no uptake (tumor \< background), minimal uptake (tumor = background), mild (tumor slightly \> background), moderate uptake (tumor \>\> background), and intense uptake (tumor \>\>\> background). Tumor uptake will also be dichotomized as increased (mild, moderate, or intense uptake) or absent (no uptake, minimal).

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3

  2. Intra- and Inter-Observer Variability of Quantitative Assessment of Tumor 18F-FFNP uptake

    For the test-retest portion of the clinical trial, the mixed effects model framework will be utilized to determine the intra- and interobserver variability of quantitative assessment of tumor 18F-FFNP uptake via a parametric bootstrapping approach.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3

  3. Quantitative Assessment of Tumor 18F-FFNP: Standardized Uptake Values (SUV)

    Differences in repeatability of the different SUV measures (SUVmax, SUVpeak, and SUVmean) and their respective methods of normalization will be assessed by comparing the variances of the relative test-retest differences, using the Pitnam-Morgan test for correlated variances.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3

  4. Test-Retest Variability of Quantitative Assessment of Tumor 18F-FFNP uptake

    For the test-retest portion of the clinical trial, the mixed effects model framework will be utilized to determine the test-retest variability of quantitative assessment of tumor 18F-FFNP uptake via a parametric bootstrapping approach.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks and up to 6 weeks for the test-retest Group 3

  5. NCIC Adverse Events Version 5.0 Frequency Tables

    Safety and tolerability of 18F-FFNP by NCIC Adverse Events Version 5.0 will be assessed by frequency tables and possible relationship to study drug as assessed by the investigators.

    Time frame: up to 7 weeks

Other outcomes

  1. Summary of Parent and Metabolite Fractions of 18F-FFNP over the course of the scan

    Median and interquartile ranges will be calculated for metabolized and unmetabolized (parent) 18F-FFNP obtained from subjects undergoing venous blood sampling in the metabolite study and plotted against time.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1

  2. Statistical Correlation between tumor 18F-FFNP uptake with serum progesterone, 17-OH progesterone, estradiol, and corticosteroid binding globulin levels

    Pearson's or Rank correlation analysis will be performed to assess the association between tumor 18F-FFNP uptake with serum progesterone, estradiol, and corticosteroid binding globulin levels. Scatter plots, correlation coefficients (rho), 95% confidence intervals, and p values will be reported.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1

  3. Statistical correlation between 18F-FFNP breast PET/MRI parameters and changes in PR immunohistochemistry in therapy responders and non-responders

    An ANCOVA model, which will include treatment as a fixed effect and the corresponding baseline value as a covariate, and a paired t-test will be utilized to compare the change in tumor 18F-FFNP update after window treatment with change in PR immunostaining from the biopsy to surgical specimen. Means and standard errors will be presented. Least-squares means and 95% CI will be reported. Furthermore, correlation analyses will be performed to describe these associations.

    Time frame: imaging takes up to 2 hours during a visit and will take place up to 4 weeks on study for Group 1, up to 4 weeks and up to 7 weeks for Group 2, and up to 4 weeks and up to 6 weeks for Group 3

  4. Statistical correlation between tumor 18F-FFNP uptake with disease recurrence

    If there is sufficient follow-up data for disease recurrence, the Kaplan-Meier method will be used to analyze time to disease recurrence, defined as date of imaging day until disease recurrence. Patients who do not experience disease recurrence will be censored at the date of last available follow-up. A Cox proportional hazards model will be used to evaluate the association of tumor 18F-FFNP uptake with time to disease recurrence. If there is insufficient follow-up data, descriptive statistics will be used to summarize tumor 18F-FFNP uptake for those patients with disease recurrence

    Time frame: up to 5 years (long term follow up)

  5. Statistical determination of whether MRI parameters improve the predictive value of FFNP PET alone

    The investigators will explore whether adding MRI parameters improves the AUC of 18F-FFNP PET alone. Regression models will be performed on the following parameters: quantitative tumor perfusion (signal enhancement ratio, functional tumor volume), quantitative tumor diffusion (apparent diffusion coefficient), qualitative morphologic phenotype (categories I, II, III, IV), and qualitative background parenchymal enhancement (categories are minimal, mild, moderate, marked).

    Time frame: up to 5 years (long term follow up)

07

Study locations

1 of 1 sites recruiting
  • UW Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Recruiting
    • Roberta M Strigel, MD, MS · Sub investigator
    • Kari B Wisinski, MD · Sub investigator
    • Lee G Wilke, MD · Sub investigator
    • Scott B Perlman, MD · Sub investigator
    • Lonie R Salkowski, MD, MS, PhD · Sub investigator
    • Aparna M Mahajan, MD · Sub investigator
    • Stephanie M McGregor, MD, PhD · Sub investigator
    • Emmanuel Sampene, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2028, 47 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 47 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Oct 17, 2023
StartActual
Sep 25, 2024
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06086704
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Sep 25, 2024
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

Cancer Connect
Contact
clinicaltrials@cancer.wisc.edu
800-622-8922
Amy M Fowler, MD, PHD
principal investigator · UW Carbone Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion